Insider Selling: Momenta Pharmaceuticals President Unloads 1,687 Shares of Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig A. Wheeler sold 1,687 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $11.09, for a total transaction of $18,708.83. Following the sale, the president now directly owns 377,852 shares in the company, valued at approximately $4,190,379. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Friday, May 9th. They set a “buy” rating and a $24.00 price target on the stock. Separately, analysts at Bank of America upgraded shares of Momenta Pharmaceuticals from an “underperform” rating to a “buy” rating in a research note on Wednesday, May 7th. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $17.00 price target on the stock, down previously from $22.00. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $20.20.
Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 0.17% on Friday, hitting $11.95. 650,077 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a 52-week low of $9.85 and a 52-week high of $19.90. The stock’s 50-day moving average is $11.3 and its 200-day moving average is $15.69. The company’s market cap is $614.8 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.02. The company had revenue of $10.79 million for the quarter, compared to the consensus estimate of $8.41 million. During the same quarter in the prior year, the company posted ($0.48) earnings per share. The company’s quarterly revenue was up 42.1% on a year-over-year basis. Analysts expect that Momenta Pharmaceuticals will post $-0.43 EPS for the current fiscal year.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.